Proteomics-based analysis of invasion-related proteins in malignant gliomas

Neuropathology

Volumn 33, Issue 3, 2013, Pages 264-275

  Maruo, Tomoko ^a   Ichikawa, Tomotsugu ^a   Kanzaki, Hirotaka ^a   Inoue, Satoshi ^a   Kurozumi, Kazuhiko ^a   Onishi, Manabu ^a   Yoshida, Koichi ^a   Kambara, Hirokazu ^a   Ouchida, Mamoru ^a   Shimizu, Kenji ^a   Tamaru, Seiji ^b   Chiocca, E Antonio ^c   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Annexin A2; Glioma; Invasion; Proteomics

Indexed keywords

3 OXOACID COENZYME A TRANSFERASE; ALDEHYDE DEHYDROGENASE; AMINOACYL TRANSFER RNA; COLLAPSIN RESPONSE MEDIATOR PROTEIN; ELONGATION FACTOR 2; FATTY ACID SYNTHASE; FERRITIN; GLUTATHIONE TRANSFERASE T1; GLYCINE AMIDINOTRANSFERASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN; SEPTIN; SULFOTRANSFERASE; TRIOSEPHOSPHATE ISOMERASE;

ANGIOGENESIS; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC SIMILARITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEOMICS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; ANNEXIN A2; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; DOGS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEOMICS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

EID: 84878643858     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2012.01361.x     Document Type: Article

References (41)

1. Inoue S, Ichikawa T, Kurozumi K etal. Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg 2012. doi: 10.1016/j.wneu.2011.09.005.
2. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011; 28: 13-24.
3. Berens ME, Bjotvedt G, Levesque DC, Rief MD, Shapiro JR, Coons SW. Tumorigenic, invasive, karyotypic, and immunocytochemical characteristics of clonal cell lines derived from a spontaneous canine anaplastic astrocytoma. In Vitro Cell Dev Biol Anim 1993; 29: 310-318.
4. Hampl JA, Camp SM, Mydlarz WK etal. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther 2003; 14: 611-626.
5. Ichikawa T, Tamiya T, Adachi Y etal. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 2000; 7: 74-82.
6. Mai J, Waisman DM, Sloane BF. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 2000; 1477: 215-230.
7. Díaz VM, Hurtado M, Thomson TM, Reventós J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004; 53: 993-1000.
8. Zhai H, Acharya S, Gravanis I etal. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci 2011; 31: 14346-14360.
9. Vogel TW, Zhuang Z, Li J etal. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 2005; 11: 3624-3632.
10. Iwadate Y, Sakaida T, Hiwasa T etal. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64: 2496-2501.
11. de Vries NA, Beijnen JH, van Tellingen O. High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev 2009; 35: 714-723.
12. Martens T, Laabs Y, Günther HS etal. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 2008; 14: 5447-5458.
13. Giannini C, Sarkaria JN, Saito A etal. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005; 7: 164-176.
14. Rescher U, Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004; 117: 2631-2639.
15. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82: 331-371.
16. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6: 449-461.
17. Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun 2004; 322: 1166-1170.
18. Hayes MJ, Longbottom RE, Evans MA, Moss SE. Annexinopathies. Subcell Biochem 2007; 45: 1-28.
19. Rand JH. The annexinopathies: a new category of diseases. Biochim Biophys Acta 2000; 1498: 169-173.
20. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008; 216: 131-140.
21. Zobiack N, Gerke V, Rescher U. Complex formation and submembranous localization of annexin 2 and S100A10 in live HepG2 cells. FEBS Lett 2001; 500: 137-140.
22. Ling Q, Jacovina AT, Deora A etal. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48.
23. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-21197.
24. Emoto K, Sawada H, Yamada Y etal. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001; 21: 1339-1345.
25. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI. Characterization and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008; 98: 426-433.
26. Esposito I, Penzel R, Chaib-Harrireche M etal. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006; 208: 673-685.
27. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006; 81: 146-156.
28. Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA. Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 1992; 52: 6871-6876.
29. Zimmermann U, Woenckhaus C, Pietschmann S etal. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 2004; 445: 368-374.
30. Syed SP, Martin AM, Haupt HM, Arenas-Elliot CP, Brooks JJ. Angiostatin receptor annexin II in vascular tumors including angiosarcoma. Hum Pathol 2007; 38: 508-513.
31. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-3358.
32. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. Traffic 2004; 5: 571-576.
33. Beckner ME, Chen X, An J, Day BW, Pollack IF. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest 2005; 85: 316-327.
34. Tatenhorst L, Rescher U, Gerke V, Paulus W. Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol Appl Neurobiol 2006; 32: 271-277.
35. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007; 13: 3568-3575.
36. Pàez-Ribes M, Allen E, Hudock J etal. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
37. Zhao S, Huang L, Wu J, Zhang Y, Pan D, Liu X. Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. Mol Vis 2009; 15: 1231-1242.
38. Carpenter B, MacKay C, Alnabulsi A etal. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 2006; 1765: 85-100.
39. Ostrowski J, Bomsztyk K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer 2003; 89: 1493-1501.
40. Kinoshita M, Kumar S, Mizoguchi A etal. Nedd5, a mammalian septin, is a novel cytoskeletal component interacting with actin-based structures. Genes Dev 1997; 11: 1535-1547.
41. Kim DS, Hubbard SL, Peraud A, Salhia B, Sakai K, Rutka JT. Analysis of mammalian septin expression in human malignant brain tumors. Neoplasia 2004; 6: 168-178.